Trial Profile

Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tafenoquine (Primary)
Indications Babesiosis; Fatigue
Focus Therapeutic Use
Acronyms B-FREE study
Sponsors 60 Degrees Pharmaceuticals

Most Recent Events

09 Oct 2025 Planned number of patients changed from 40 to 100.
09 Oct 2025 According to a 60 Degrees Pharma media release, company announced today the name of its chronic babesiosis trial is the B-FREE Chronic Babesiosis Study. B-FREE, a Phase 2 trial, will commence in early November and run for approximately 12 months.
08 Oct 2025 Planned initiation date changed from 1 Jan 2026 to 1 Nov 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com